TY - JOUR
T1 - Clinicopathological characteristics of the SOX10+ subset of HER2+ breast cancer
AU - Weisman, Paul
AU - Yu, Qiqi
AU - Xu, Jin
N1 - Funding Information:
The study was made possible by support from the University of Wisconsin-Madison Translational Research in Pathology laboratory, specifically Toshi Kinoshita and Vishal Chanana who performed immunohistochemical stains. The UW-Madison Department of Pathology provided resources for completion of this study.
Funding Information:
This study was supported by research funds from the Department of Pathology and Laboratory Medicine at UW-Madison .
Publisher Copyright:
© 2022 Elsevier Inc.
PY - 2023/4
Y1 - 2023/4
N2 - HER2-positive breast cancers (HER2+ BC) are a heterogeneous group of tumors with variable clinical behavior. SOX10, a biomarker that has been studied in the context of breast carcinomas, especially triple-negative breast carcinomas (TNBC), has yet to be systematically investigated in a cohort of HER2+ BC. Our aim was to investigate the clinicopathological features of the SOX10+ subset of HER2+ BC. 80 HER2+/ER- invasive breast carcinomas were stained for SOX10. All SOX10+ cases and a matched number of SOX10- cases were also stained for vimentin and androgen receptor (AR). 18 % (14/80) of our cases were SOX10+. SOX10 expression was seen in both IHC positive (3+) and equivocal (2+) but ISH-amplified cases. The SOX10+ tumors were significantly associated with both greater vimentin expression (36 % vs 0 %, p = 0.0407) and less AR expression (14 % vs 100 %, p = 0.0001) compared to SOX10- tumors. Interestingly, the vimentin+/AR- subset of our SOX10+ cases showed uniformly apocrine-like morphology, while all SOX10- cases, including those with apocrine-like morphology, were vimentin-/AR+. Our findings suggest that SOX10+/HER2+ BC are more likely to show a peculiar apocrine-like, vimentin+/AR- phenotype as compared to SOX10-/HER2+ BC.
AB - HER2-positive breast cancers (HER2+ BC) are a heterogeneous group of tumors with variable clinical behavior. SOX10, a biomarker that has been studied in the context of breast carcinomas, especially triple-negative breast carcinomas (TNBC), has yet to be systematically investigated in a cohort of HER2+ BC. Our aim was to investigate the clinicopathological features of the SOX10+ subset of HER2+ BC. 80 HER2+/ER- invasive breast carcinomas were stained for SOX10. All SOX10+ cases and a matched number of SOX10- cases were also stained for vimentin and androgen receptor (AR). 18 % (14/80) of our cases were SOX10+. SOX10 expression was seen in both IHC positive (3+) and equivocal (2+) but ISH-amplified cases. The SOX10+ tumors were significantly associated with both greater vimentin expression (36 % vs 0 %, p = 0.0407) and less AR expression (14 % vs 100 %, p = 0.0001) compared to SOX10- tumors. Interestingly, the vimentin+/AR- subset of our SOX10+ cases showed uniformly apocrine-like morphology, while all SOX10- cases, including those with apocrine-like morphology, were vimentin-/AR+. Our findings suggest that SOX10+/HER2+ BC are more likely to show a peculiar apocrine-like, vimentin+/AR- phenotype as compared to SOX10-/HER2+ BC.
KW - Breast carcinoma
KW - HER2+
KW - SOX10
UR - http://www.scopus.com/inward/record.url?scp=85146605249&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85146605249&partnerID=8YFLogxK
U2 - 10.1016/j.anndiagpath.2022.152087
DO - 10.1016/j.anndiagpath.2022.152087
M3 - Article
C2 - 36669230
AN - SCOPUS:85146605249
SN - 1092-9134
VL - 63
JO - Annals of Diagnostic Pathology
JF - Annals of Diagnostic Pathology
M1 - 152087
ER -